OKYO Pharma Limited (NASDAQ:OKYO – Get Free Report) dropped 0.4% on Wednesday . The stock traded as low as $1.03 and last traded at $1.04. Approximately 47,118 shares traded hands during trading, a decline of 63% from the average daily volume of 127,017 shares. The stock had previously closed at $1.04.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a research report on Thursday, October 24th.
Get Our Latest Stock Report on OKYO Pharma
OKYO Pharma Stock Performance
About OKYO Pharma
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Featured Stories
- Five stocks we like better than OKYO Pharma
- How to Invest in Biotech Stocks
- Oracle Announces Game-Changing News for the AI Industry
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- What is a Low P/E Ratio and What Does it Tell Investors?
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
